Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -1.87 is 18% above its 5-year average of -2.28, near the high end of its 5-year range (-6.46–0.00).
111.49% below its 12-month average of -0.88.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.32.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T14:42:40.608Z. Historical observations retain their original dates. Historical series through 2025-05-08.
EARNINGS PER SHARE (EPS)
-1.87
EARNINGS PER SHARE (EPS) AVG TTM
-0.88
EARNINGS PER SHARE (EPS) AVG 3Y
-1.76
EARNINGS PER SHARE (EPS) AVG 5Y
-2.28
EARNINGS PER SHARE (EPS) AVG 10Y
-7.80
EARNINGS PER SHARE (EPS) AVG 15Y
-8.39
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
-111.49%
CURRENT VS 3Y AVG
-5.97%
CURRENT VS 5Y AVG
+18.15%
CURRENT VS 10Y AVG
+76.04%
CURRENT VS 15Y AVG
+77.72%
CURRENT VS 20Y AVG
N/A
Lipocine Inc.
Market Cap
$17.15M
Earnings Per Share (EPS)
-1.87
TTM Avg
-0.88
3Y Avg
-1.76
5Y Avg
-2.28
Market Cap
$17.09M
Earnings Per Share (EPS)
-0.48
TTM Avg
-0.99
3Y Avg
-1.87
5Y Avg
-3.18
Market Cap
$16.75M
Earnings Per Share (EPS)
-3.73
TTM Avg
-46.49
3Y Avg
-194.14
5Y Avg
-195.03
Market Cap
$16.85M
Earnings Per Share (EPS)
-0.21
TTM Avg
-0.22
3Y Avg
-0.25
5Y Avg
-0.30
Market Cap
$15.88M
Earnings Per Share (EPS)
-0.76
TTM Avg
-2.06
3Y Avg
-5.59
5Y Avg
-9.29
Market Cap
$15.91M
Earnings Per Share (EPS)
-0.78
TTM Avg
-8.29
3Y Avg
-9461.74
5Y Avg
-302593.36
Market Cap
$18.70M
Earnings Per Share (EPS)
-7.26
TTM Avg
-1.65
3Y Avg
-0.89
5Y Avg
-0.63
Market Cap
$18.82M
Earnings Per Share (EPS)
-10.58
TTM Avg
-21.77
3Y Avg
-25.72
5Y Avg
-24.83
Market Cap
$15.44M
Earnings Per Share (EPS)
-0.77
TTM Avg
-1.25
3Y Avg
-1.82
5Y Avg
-1.86
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lipocine Inc. (LPCN) | $17.15M | -1.87 | -0.88 | -1.76 | -2.28 |
| Marker Therapeutics, Inc. (MRKR)vs › | $17.09M | -0.48 | -0.99 | -1.87 | -3.18 |
| Bionano Genomics, Inc. (BNGO)vs › | $16.75M | -3.73 | -46.49 | -194.14 | -195.03 |
| Dyadic International, Inc. (DYAI)vs › | $16.85M | -0.21 | -0.22 | -0.25 | -0.30 |
| BioCardia, Inc. (BCDA)vs › | $15.88M | -0.76 | -2.06 | -5.59 | -9.29 |
| Allarity Therapeutics, Inc. (ALLR)vs › | $15.91M | -0.78 | -8.29 | -9461.74 | -302593.36 |
| Neuphoria Therapeutics Inc. (NEUP)vs › | $18.70M | -7.26 | -1.65 | -0.89 | -0.63 |
| NextCure, Inc. (NXTC)vs › | $18.82M | -10.58 | -21.77 | -25.72 | -24.83 |
| Cocrystal Pharma, Inc. (COCP)vs › | $15.44M | -0.77 | -1.25 | -1.82 | -1.86 |
| Cosmos Health Inc. (COSM)vs › | $18.54M | -0.66 | -0.90 | -9.28 | -9.88 |
Trailing EPS (TTM)
$-1.87
Forward EPS (Est.)
$-1.54
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -1.77 |
| 2024-12-31 | 0.00 |
| 2023-12-31 | -3.14 |
| 2022-12-31 | -2.15 |
| 2021-12-31 | -0.19 |
| 2020-12-31 | -6.46 |
| 2019-12-31 | -8.54 |
| 2018-12-31 | -9.35 |
| 2017-12-31 | -17.79 |
| 2016-12-31 | -17.66 |
| 2015-12-31 | -18.79 |
| 2014-12-31 | -27.13 |
| 2013-12-31 | -24.45 |
| 2012-12-31 | 14.45 |
| 2011-12-31 | -2.93 |
